FOR IMMEDIATE RELEASE
inSeption Group Forms Scientific Advisory Board, Welcoming Industry Trailblazers to Help Redefine Drug Development
Audubon, PA — August 14, 2025 — inSeption Group, a specialized outsourcing company focused on complex clinical development programs, is proud to announce the formation of its first Scientific Advisory Board. As inSeption continues to expand its impact on emerging and midsize biopharma, the creation of the Advisory Board reflects its commitment to driving smarter, leaner, and more collaborative approaches to clinical development.
Comprised of accomplished, forward-thinking experts from across the biotech and pharmaceutical sectors, the Advisory Board will play a critical role in guiding the organization’s strategic direction as it continues to redefine traditional CRO models.
The members of the Advisory Board include:
Kenneth Getz, MBA
An internationally recognized expert in clinical trial management and outsourcing trends, and a thought leader in clinical trial innovation, Mr. Getz has spent more than two decades advancing best practices in protocol design, site engagement, and development. He is the Executive Director of the Tufts Center for the Study of Drug Development and a Professor at Tufts University School of Medicine.
Carrie Brownstein, MD
A distinguished hematologist-oncologist and former Chief Medical Officer at Zentalis Pharmaceuticals and Cellectis, Dr. Brownstein brings deep expertise in both early- and late-stage drug development. She currently serves as Senior Vice President at SSI Strategy and Principal Consultant at CMB BioPharma Solutions.
Ed Tucker, MD, MBA
With over 30 years of clinical and operational leadership, Dr. Tucker has held Chief Medical Officer roles at Goldfinch Bio, Mirum Pharmaceuticals (where he led the first FDA approval for Alagille Syndrome) and Jasper Therapeutics.
“The formation of this board marks a significant milestone in our evolution,” said Joe Arcangelo, Co-Founder and Managing Partner at inSeption Group. “We’ve always aimed to break the mold of traditional outsourcing, and now we’re aligning with some of the most respected minds in the industry to elevate that mission even further. Their insight will directly shape how we serve clients, address inefficiencies, and bring promising therapies to patients more effectively.”
“Our new board isn’t just a stamp of credibility—it’s a signal of our intention to lead change,” added Brian Sulpizio, Co-Founder and Managing Partner. “These individuals understand the nuances, the frustrations, and the real-world impact of ineffective outsourcing models. With their guidance, we’re better equipped than ever to rewrite that playbook.”
The Advisory Board will provide high-level clinical, operational, and strategic counsel to ensure inSeption remains aligned with industry needs while staying true to its core values of transparency, trust, and expert-led execution.
“inSeption is addressing what’s broken in the traditional CRO model,” said Dr. Carrie Brownstein. “Their culture, rooted in trust, quality, and collaboration, strongly reflects the values I care about in drug development. I’m excited to collaborate with this team to help shape smarter, more effective solutions.”
“It’s an opportunity to deepen understanding in a space I care deeply about, and to explore better ways of working in today’s resource-constrained environment,” added Dr. Ed Tucker. “I look forward to contributing sponsor-side perspective and helping advance a more collaborative and efficient outsourcing-sponsor relationship.”
The Advisory Board will convene regularly to assess emerging industry trends, provide strategic guidance on growth priorities, and contribute to the development of practical, forward-thinking solutions to today’s most pressing drug development challenges.
As inSeption continues to grow, the formation of the board reinforces the company’s core belief that high-performing execution, shared accountability, and genuine collaboration are not only achievable—but essential to advancing clinical development.
About inSeption Group
inSeption Group is a full-service clinical outsourcing partner purpose-built to support complex therapeutic areas and fast-moving emerging to midsize biopharma sponsors. Delivering comprehensive drug development services worldwide, inSeption rejects traditional outsourcing inefficiencies in favor of a lean, accountable model driven by expertise, integrity, and transparency. By building cohesive teams of seasoned professionals, inSeption accelerates clinical development and regulatory success through smarter, more effective execution.
For media inquiries, contact:
Kristin Morris
Senior Director, Corporate Communications
267-397-8980
kmorris@inseptiongroup.com
inseptiongroup.com